The Relationship between 25-Hydroxy Vitamin D Serum Level and Memory in Patients with a First Episode of Schizophrenia Spectrum Disorder

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023752%3A_____%2F25%3A43921567" target="_blank" >RIV/00023752:_____/25:43921567 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/25:43928562

Výsledek na webu

<a href="https://karger.com/nps/article/doi/10.1159/000545815/927606/The-Relationship-between-25-Hydroxy-Vitamin-D" target="_blank" >https://karger.com/nps/article/doi/10.1159/000545815/927606/The-Relationship-between-25-Hydroxy-Vitamin-D</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1159/000545815" target="_blank" >10.1159/000545815</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The Relationship between 25-Hydroxy Vitamin D Serum Level and Memory in Patients with a First Episode of Schizophrenia Spectrum Disorder

Popis výsledku v původním jazyce

Introduction: The relationship between vitamin D levels and cognition in young patients with schizophrenia remains incompletely understood. We explored the association between serum 25-hydroxy vitamin D concentration and long-term memory (i.e., 30-min delayed recall in the Rey Auditory Verbal Learning Test) in patients with first-episode schizophrenia. The body mass index was measured due to the accumulation of vitamin D in fat. Methods: Forty-six male participants aged 20.9 ± 2.3 years old with first-episode schizophrenia spectrum disorder were recruited. The median body mass index was 24.1, and 25-hydroxy vitamin D was 39.3 nmol/L. The mean delayed recall was 7.6 ± 3.4 words. Serum 25-hydroxy vitamin D concentration and memory performance were below the normative values for healthy adults. 25-hydroxy vitamin D concentrations and ten clinical variables were included as independent variables, and delayed recall values were included as dependent variables in the multiple regression analysis. Results: Regression analysis revealed a statistically significant link between 25-hydroxy vitamin D concentration, benzodiazepine use, and delayed recall, but not for other clinical variables. Conclusion: We found a positive association between 25-hydroxy vitamin D serum concentration and delayed recall in patients with first-episode schizophrenia, supporting a need for interventional study investigating vitamin D supplementation for the cognition of patients with schizophrenia. A negative association between benzodiazepine intake and memory performance calls for attention to minimalize benzodiazepine use.

Název v anglickém jazyce

The Relationship between 25-Hydroxy Vitamin D Serum Level and Memory in Patients with a First Episode of Schizophrenia Spectrum Disorder

Popis výsledku anglicky

Introduction: The relationship between vitamin D levels and cognition in young patients with schizophrenia remains incompletely understood. We explored the association between serum 25-hydroxy vitamin D concentration and long-term memory (i.e., 30-min delayed recall in the Rey Auditory Verbal Learning Test) in patients with first-episode schizophrenia. The body mass index was measured due to the accumulation of vitamin D in fat. Methods: Forty-six male participants aged 20.9 ± 2.3 years old with first-episode schizophrenia spectrum disorder were recruited. The median body mass index was 24.1, and 25-hydroxy vitamin D was 39.3 nmol/L. The mean delayed recall was 7.6 ± 3.4 words. Serum 25-hydroxy vitamin D concentration and memory performance were below the normative values for healthy adults. 25-hydroxy vitamin D concentrations and ten clinical variables were included as independent variables, and delayed recall values were included as dependent variables in the multiple regression analysis. Results: Regression analysis revealed a statistically significant link between 25-hydroxy vitamin D concentration, benzodiazepine use, and delayed recall, but not for other clinical variables. Conclusion: We found a positive association between 25-hydroxy vitamin D serum concentration and delayed recall in patients with first-episode schizophrenia, supporting a need for interventional study investigating vitamin D supplementation for the cognition of patients with schizophrenia. A negative association between benzodiazepine intake and memory performance calls for attention to minimalize benzodiazepine use.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30215 - Psychiatry

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Neuropsychobiology

ISSN

0302-282X

e-ISSN

1423-0224

Svazek periodika

84

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

9

Strana od-do

158-166

Kód UT WoS článku

001516961600001

EID výsledku v databázi Scopus

2-s2.0-105009859337